Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | REGN4018 + REGN5668 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
REGN4018 | REGN-4018|REGN 4018|Ubamatamab | CD3 Antibody 107 MUC16 Targeted Therapy 10 | REGN4018 is a bispecific antibody that binds MUC16 (CA125) on tumor cells and CD3 on T-cells to stimulate T-cell killing of MUC16-expressing tumor cells (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1777, PMID: 31217340). | |
REGN5668 | REGN 5668|REGN-5668 | MUC16 Targeted Therapy 10 | REGN5668 is a bispecific monoclonal antibody that targets both CD28 and MUC16 (CA125), resulting in cross-linking of CD28-positive T-cells to MUC16-expressing tumor cells, potentially leading to enhanced cytotoxic response against MUC16-positive tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04590326 | Phase Ib/II | REGN4018 + REGN5668 Cemiplimab + REGN5668 | Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer. | Recruiting | USA | FRA | ESP | BEL | 0 |